JPH08507685A - ひとパピローマウイルス・カプシド蛋白およびウイルス様粒子の製造 - Google Patents

ひとパピローマウイルス・カプシド蛋白およびウイルス様粒子の製造

Info

Publication number
JPH08507685A
JPH08507685A JP6520236A JP52023694A JPH08507685A JP H08507685 A JPH08507685 A JP H08507685A JP 6520236 A JP6520236 A JP 6520236A JP 52023694 A JP52023694 A JP 52023694A JP H08507685 A JPH08507685 A JP H08507685A
Authority
JP
Japan
Prior art keywords
hpv
papillomavirus
virus
cells
recombinant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP6520236A
Other languages
English (en)
Japanese (ja)
Inventor
ローズ、ロバート・シー
ボーンズ、ウイリアム
ライクマン、リチャード・シー
Original Assignee
ユニバーシティ・オブ・ロチェスター
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26703787&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JPH08507685(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/028,517 external-priority patent/US8062642B1/en
Application filed by ユニバーシティ・オブ・ロチェスター filed Critical ユニバーシティ・オブ・ロチェスター
Publication of JPH08507685A publication Critical patent/JPH08507685A/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
JP6520236A 1993-03-09 1994-03-08 ひとパピローマウイルス・カプシド蛋白およびウイルス様粒子の製造 Withdrawn JPH08507685A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US08/028,517 1993-03-09
US08/028,517 US8062642B1 (en) 1993-03-09 1993-03-09 Production of papillomavirus capsid protein and virus-like particles
US20730994A 1994-03-07 1994-03-07
US08/207,309 1994-03-07
PCT/US1994/002443 WO1994020137A1 (en) 1993-03-09 1994-03-08 Production of human papillomavirus capsid protein and virus-like particles

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2006277056A Division JP4486075B2 (ja) 1993-03-09 2006-10-11 ひとパピローマウイルス・カプシド蛋白およびウイルス様粒子の製造

Publications (1)

Publication Number Publication Date
JPH08507685A true JPH08507685A (ja) 1996-08-20

Family

ID=26703787

Family Applications (4)

Application Number Title Priority Date Filing Date
JP6520236A Withdrawn JPH08507685A (ja) 1993-03-09 1994-03-08 ひとパピローマウイルス・カプシド蛋白およびウイルス様粒子の製造
JP2006277056A Expired - Lifetime JP4486075B2 (ja) 1993-03-09 2006-10-11 ひとパピローマウイルス・カプシド蛋白およびウイルス様粒子の製造
JP2010023690A Expired - Lifetime JP5306251B2 (ja) 1993-03-09 2010-02-05 ひとパピローマウイルス・カプシド蛋白およびウイルス様粒子の製造
JP2010023691A Expired - Lifetime JP5386392B2 (ja) 1993-03-09 2010-02-05 ひとパピローマウイルス・カプシド蛋白およびウイルス様粒子の製造

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2006277056A Expired - Lifetime JP4486075B2 (ja) 1993-03-09 2006-10-11 ひとパピローマウイルス・カプシド蛋白およびウイルス様粒子の製造
JP2010023690A Expired - Lifetime JP5306251B2 (ja) 1993-03-09 2010-02-05 ひとパピローマウイルス・カプシド蛋白およびウイルス様粒子の製造
JP2010023691A Expired - Lifetime JP5386392B2 (ja) 1993-03-09 2010-02-05 ひとパピローマウイルス・カプシド蛋白およびウイルス様粒子の製造

Country Status (13)

Country Link
EP (3) EP0688227B1 (enExample)
JP (4) JPH08507685A (enExample)
AT (3) ATE492289T1 (enExample)
AU (3) AU688759C (enExample)
CA (1) CA2157932C (enExample)
DE (9) DE122007000089I1 (enExample)
DK (2) DK0688227T3 (enExample)
ES (3) ES2242955T4 (enExample)
FR (1) FR11C0022I2 (enExample)
LU (3) LU91313I2 (enExample)
NL (3) NL300265I2 (enExample)
PT (2) PT688227E (enExample)
WO (1) WO1994020137A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002516291A (ja) * 1998-05-29 2002-06-04 ユニバーシティー オブ ロチェスター パピローマウイルス・ウイルス様粒子による経口免疫感作
JP2004510144A (ja) * 2000-09-18 2004-04-02 メディミューン，インコーポレイテッド ワクチンの免疫原性を測定する試験管内検定
JP2010095530A (ja) * 1997-10-06 2010-04-30 Loyola Univ Of Chicago パピローマウイルスカプソメアワクチン製剤および使用方法

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0595935T3 (da) 1991-07-19 2003-07-21 Csl Ltd Papillomavirusvaccine
US5437951A (en) * 1992-09-03 1995-08-01 The United States Of America As Represented By The Department Of Health And Human Services Self-assembling recombinant papillomavirus capsid proteins
AUPM358894A0 (en) * 1994-01-31 1994-02-24 Csl Limited Modified papilloma virus l2 protein and vlps formed therefrom
DE4415743C2 (de) 1994-05-04 1996-10-10 Deutsches Krebsforsch Papillomviren, Mittel zu deren Nachweis sowie zur Therapie von durch sie verursachten Erkrankungen
US5888516A (en) * 1994-05-16 1999-03-30 Merck & Co. Inc. Recombinant papillomavirus vaccines
AUPM566794A0 (en) * 1994-05-17 1994-06-09 University Of Queensland, The Process and product
AU4270196A (en) * 1994-10-07 1996-05-02 Lutz Gissmann Papilloma virus-like particles, fusion proteins and process for producing the same
AU2003235191B2 (en) * 1994-10-07 2006-09-21 Loyola University Of Chicago Papilloma virus-like particles, fusion proteins as well as processes for their production
AR004464A1 (es) * 1994-11-14 1998-12-16 Merck Sharp & Dohme Un metodo para producir una proteina de capside de papilomavirus
US5955087A (en) * 1995-02-24 1999-09-21 Cantab Pharmaceuticals Research Limited Polypeptides useful as immunotherapeutic agents and methods of polypeptide preparation
IL117459A (en) * 1995-03-22 2005-11-20 Merck & Co Inc Dna encoding human papillomavirus type 18
US5840306A (en) * 1995-03-22 1998-11-24 Merck & Co., Inc. DNA encoding human papillomavirus type 18
US5820870A (en) * 1995-03-22 1998-10-13 Merck & Co., Inc. Recombinant human papillomavirus type 18 vaccine
IL117591A0 (en) * 1995-03-30 1996-07-23 Merck & Co Inc Synthetic DNA encoding human papillomavirus type 11 L1 protein
US5821087A (en) * 1995-03-30 1998-10-13 Merck & Co., Inc. Production of recombinant human papillomavirus type II protein utilizing papillomavirus 6/11 hybrid DNA
EP0863982B1 (en) * 1995-11-15 2004-01-21 Merck & Co., Inc. Synthetic hpv11 virus-like particles
DE19543553B4 (de) * 1995-11-22 2009-04-09 Deutsches Primatenzentrum Gmbh VP-Antigene des JC-Virus
US6908615B1 (en) 1996-03-18 2005-06-21 Merck & Co., Inc. DNA encoding human papilloma virus type 18
FR2749323B1 (fr) * 1996-06-04 1998-07-10 Pasteur Merieux Serums Vacc Pseudo-particules virales utiles en tant que vecteur de delivrance d'acide nucleique
EP0956349B1 (en) * 1996-10-04 2003-12-17 Merck & Co., Inc. (a New Jersey corp.) Synthetic hpv16 virus-like particles
ES2213841T3 (es) * 1996-12-09 2004-09-01 MERCK & CO., INC. Particulas sinteticas semejantes al virus hpv16.
US7494658B2 (en) 1998-02-20 2009-02-24 Medigene Ag Papilloma virus truncated L1 protein and fusion protein constructs
US20020039584A1 (en) 1998-02-20 2002-04-04 Medigene Ag Papilloma virus capsomere vaccine formulations and methods of use
US7182947B2 (en) 1998-02-20 2007-02-27 Medigene Ag Papillomavirus truncated L1 protein and fusion protein constructs
CA2229955C (en) 1998-02-20 2003-12-09 Medigene Gmbh Papilloma virus capsomere vaccine formulations and methods of use
US6926897B1 (en) 1998-03-24 2005-08-09 Medigene Aktiengesellschaft Medicament for the avoidance or treatment of papillomavirus-specific tumour
US6692752B1 (en) 1999-09-08 2004-02-17 Smithkline Beecham Biologicals S.A. Methods of treating human females susceptible to HSV infection
DE19925199A1 (de) 1999-06-01 2000-12-07 Medigene Ag Zytotoxische T-Zellepitope des Papillomavirus L1-Proteins und ihre Verwendung in Diagnostik und Therapie
DE19925235A1 (de) 1999-06-01 2000-12-07 Medigene Ag Zytotoxische T-Zellepitope des Papillomavirus L1-Proteins und ihre Verwendung in Diagnostik und Therapie
GB0109297D0 (en) 2001-04-12 2001-05-30 Glaxosmithkline Biolog Sa Vaccine
CA2457804C (en) 2001-08-13 2012-10-16 University Of Rochester Transcutaneous immunization against papillomavirus with papillomavirus virus-like particles
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
US7534585B2 (en) 2003-07-21 2009-05-19 Transgene S.A. Multifunctional cytokines
WO2006113209A1 (en) 2005-04-15 2006-10-26 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods and compositions for producing an enhanced immune response to a human papillomavirus immunogen
WO2006065166A1 (en) * 2005-07-26 2006-06-22 Obschestvo S Ogranichennoi Otvetstvennostyu 'rusgen' Protein l1 and protein e7 peptide-based composition for treating and preventing a human papillomaviral infection
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
US8778351B2 (en) 2006-08-30 2014-07-15 University Of Rochester Combined human papillomavirus VLP/gene delivery system and use thereof as a vaccine for prophylaxis and immunotherapy of infectious diseases and tumors
SI2468300T1 (en) 2006-09-26 2018-03-30 Infectios Disease Research Institute A vaccine composition comprising a synthetic adjuvant
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
HRP20161606T1 (hr) 2007-03-02 2017-01-13 Glaxosmithkline Biologicals Sa Novi postupak i pripravci
CN101570571B (zh) 2007-04-29 2012-07-11 北京万泰生物药业股份有限公司 截短的人乳头瘤病毒18型l1蛋白
US9428555B2 (en) 2007-04-29 2016-08-30 Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. Truncated L1 protein of Human Papillomavirus type 16
DK2154149T3 (da) 2007-05-29 2019-10-14 Univ Xiamen En trunkeret l1-protein af human papillomavirus 6
BRPI0810959B1 (pt) 2007-05-29 2021-06-29 Xiamen Innovax Biotech Co., Ltd. Proteína l1 do hpv11, polinucleotídeo, vetor, célula, composição, partícula do tipo vírus (vlp) hpv11, método para produzir uma proteína l1 do hpv, vacina para prevenção de condiloma acuminado ou de infecções por hpv e método para produzir uma vacina para prevenção de condiloma acuminado ou infecções por hpv
US20110091496A1 (en) * 2008-01-19 2011-04-21 Graham Barney S Methods and compositions for the delivery of vaccines to disrupted epithelium
US9623098B2 (en) 2008-05-26 2017-04-18 Cadila Healthcare Limited Combined measles-human papilloma vaccine
GB0815872D0 (en) 2008-09-01 2008-10-08 Pasteur Institut Novel method and compositions
GB0820822D0 (en) 2008-11-13 2008-12-24 Inst Catala D Oncologia Novel product and processes
US20120115207A1 (en) * 2009-04-03 2012-05-10 Deutsches Krebsforschungszentrum Enhanced production of papillomavirus-like particles with a modified baculovirus expression system
BRPI1011072B1 (pt) 2009-06-05 2021-09-28 Infectious Disease Research Institute Composto de gla, composições de vacina e farmacêutica compreendendo dito composto, bem como uso dos mesmos para estimular, induzir ou acentuar uma resposta imune em um indivíduo
WO2011026111A1 (en) 2009-08-31 2011-03-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Oral delivery of a vaccine to the large intestine to induce mucosal immunity
WO2011127360A1 (en) 2010-04-08 2011-10-13 University Of Pittsburgh-Of The Commonwealth System Of Higher Education B-cell antigen presenting cell assay
WO2012141984A1 (en) 2011-04-08 2012-10-18 Immune Design Corp. Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
WO2013119856A1 (en) 2012-02-07 2013-08-15 Infectious Disease Research Institute Improved adjuvant formulations comprising tlr4 agonists and methods of using the same
JP2015514696A (ja) 2012-03-18 2015-05-21 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ヒト・パピローマウイルスに対するワクチン接種方法
US9895435B2 (en) 2012-05-16 2018-02-20 Immune Design Corp. Vaccines for HSV-2
WO2014066443A1 (en) 2012-10-23 2014-05-01 Emory University Gm-csf and il-4 conjugates, compositions, and methods related thereto
JP6426706B2 (ja) 2013-04-18 2018-11-21 イミューン デザイン コーポレイション がん処置で使用するためのｇｌａ単剤療法
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
IL310015B1 (en) 2013-12-31 2025-10-01 Access To Advanced Health Inst Single vial formulation
CN108885212B (zh) 2016-02-22 2022-05-31 勃林格殷格翰维特梅迪卡有限公司 固定生物分子的方法
EP3458475B1 (en) 2016-05-16 2022-07-27 Access to Advanced Health Institute Formulation containing tlr agonist and methods of use
US11266602B2 (en) 2016-05-16 2022-03-08 Infectious Disease Research Institute PEGylated liposomes and methods of use
US11173126B2 (en) 2016-06-01 2021-11-16 Infectious Disease Research Institute Nanoalum particles comprising a PAA sizing agent
KR20240096685A (ko) 2017-06-15 2024-06-26 액세스 투 어드밴스드 헬스 인스티튜트 나노구조 지질 담체 및 안정적인 에멀션 그리고 이들의 용도
US20200276299A1 (en) 2017-09-08 2020-09-03 Infectious Disease Research Institute Liposomal formulations comprising saponin and methods of use
US12318436B2 (en) 2019-05-25 2025-06-03 Access To Advanced Health Institute Composition and method for spray drying an adjuvant vaccine emulsion
WO2022051022A1 (en) 2020-09-04 2022-03-10 Infectious Disease Research Institute Co-lyophilized rna and nanostructured lipid carrier
CA3210363A1 (en) 2021-02-11 2022-08-18 Glaxosmithkline Biologicals Sa Hpv vaccine manufacture
IL319329A (en) 2022-09-09 2025-05-01 Access To Advanced Health Inst Immunogenic vaccine composition incorporating saponin
CN116375816B (zh) * 2023-01-06 2023-09-05 北京康乐卫士生物技术股份有限公司 一种人乳头瘤病毒56型l1蛋白突变体及减少重组蛋白降解的方法及应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4956288A (en) * 1988-04-22 1990-09-11 Biogen, Inc. Method for producing cells containing stably integrated foreign DNA at a high copy number, the cells produced by this method, and the use of these cells to produce the polypeptides coded for by the foreign DNA
NZ232913A (en) 1989-03-15 1992-08-26 Gist Brocades Nv Il-3 produced recombinantly and purified to homogeneity; vectors and pharmaceutical preparations
DK0595935T3 (da) * 1991-07-19 2003-07-21 Csl Ltd Papillomavirusvaccine

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010095530A (ja) * 1997-10-06 2010-04-30 Loyola Univ Of Chicago パピローマウイルスカプソメアワクチン製剤および使用方法
JP2002516291A (ja) * 1998-05-29 2002-06-04 ユニバーシティー オブ ロチェスター パピローマウイルス・ウイルス様粒子による経口免疫感作
JP2004510144A (ja) * 2000-09-18 2004-04-02 メディミューン，インコーポレイテッド ワクチンの免疫原性を測定する試験管内検定

Also Published As

Publication number Publication date
AU2007201005A1 (en) 2007-03-29
FR11C0022I1 (enExample) 2011-05-08
AU688759B2 (en) 1998-03-19
ES2263405T1 (es) 2006-12-16
DE05075369T1 (de) 2006-11-16
NL300309I1 (nl) 2008-02-01
EP0688227A1 (en) 1995-12-27
ES2242955T3 (es) 2005-11-16
CA2157932A1 (en) 1994-09-15
DE05075889T1 (de) 2006-10-05
NL300309I2 (nl) 2008-03-03
NL300265I2 (nl) 2008-05-01
AU2007201006B2 (en) 2010-07-01
ES2242955T4 (es) 2010-04-12
JP2010148514A (ja) 2010-07-08
ATE492289T1 (de) 2011-01-15
LU91313I2 (fr) 2007-04-23
DE122011100018I1 (de) 2011-11-17
WO1994020137A1 (en) 1994-09-15
PT688227E (pt) 2005-10-31
EP1588713A1 (en) 2005-10-26
DE69434383D1 (de) 2005-06-30
DK0688227T3 (da) 2005-06-27
AU2007201006A1 (en) 2007-03-29
AU2007201005B2 (en) 2010-06-10
DE69435331D1 (de) 2011-02-03
ATE296111T1 (de) 2005-06-15
EP0688227A4 (en) 1996-05-29
NL300265I1 (nl) 2007-05-01
LU91391I2 (fr) 2008-02-14
LU91392I2 (fr) 2008-02-14
JP4486075B2 (ja) 2010-06-23
EP1588713B1 (en) 2010-12-22
HK1082206A1 (en) 2006-06-02
HK1082196A1 (en) 2006-06-02
DE69434383T2 (de) 2005-11-24
ES2263406T1 (es) 2006-12-16
JP2010099091A (ja) 2010-05-06
ES2263405T3 (es) 2011-04-20
DE122007000014I1 (de) 2007-05-24
EP0688227B1 (en) 2005-05-25
DE69435332D1 (de) 2011-02-17
ES2263406T3 (es) 2011-06-06
DK1618888T3 (da) 2011-04-04
NL300310I1 (nl) 2008-02-01
PT1618888E (pt) 2011-04-08
JP2007075117A (ja) 2007-03-29
ATE494005T1 (de) 2011-01-15
JP5306251B2 (ja) 2013-10-02
AU688759C (en) 2006-12-21
EP1618888A1 (en) 2006-01-25
DE122007000089I1 (de) 2008-03-27
DE122007000090I1 (de) 2008-03-27
AU6443694A (en) 1994-09-26
EP1618888B1 (en) 2011-01-05
CA2157932C (en) 2011-10-11
JP5386392B2 (ja) 2014-01-15
FR11C0022I2 (fr) 2012-08-03

Similar Documents

Publication Publication Date Title
JP5386392B2 (ja) ひとパピローマウイルス・カプシド蛋白およびウイルス様粒子の製造
JP4046949B2 (ja) 自己組立て組換えパピローマウイルスキャプシッド蛋白質
US7169585B2 (en) Papillomavirus vaccine
US6153201A (en) Oral immunization with papillomavirus virus-like particles
US8062642B1 (en) Production of papillomavirus capsid protein and virus-like particles
AU683220C (en) Self-assembling recombinant papillomavirus capsid proteins
HK1082196B (en) Production of human papillomavirus hbv-11 capsid protein l1 and virus-like particles
HK1082206B (en) Production of human papillomavirus capsid protein and virus-like particles
HK1079239A (en) Self-assembling recombinant hpv16 papillomavirus capsid proteins

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20050322

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20050620

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20050620

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20050620

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050922

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20051017

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20060613

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060911

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20061025

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20061025

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20061214

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20070215

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20081107